Free Republic

The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine on Dec. 11, 2020. A week later, the FDA issued an EUA for Moderna's COVID-19 vaccine. Now, nearly two years later, Pfizer and Moderna will launch clinical trials to track adverse health issues stemming from the COVID-19 vaccines, such as myocarditis – inflammation of the heart muscle. Pfizer is in the infancy of beginning clinical trials to determine if there are any health risks associated with their own vaccine. In a partnership with the Pediatric Heart Network, the trial will focus on...

It all started with a simple admission. Pfizer CEO Albert Bourla joined Yahoo Finance’s Anjalee Khemlani to discuss vaccines, boosters, and Omicron. He admitted what we already know based on the results we’ve been seeing, but in doing so he opened up a can of worms. Here’s what he said, emphasis added: “So — and we know that the two doses of the vaccine offer very limited protection, if any. The three doses, with the booster, they offer reasonable protection against hospitalization and deaths — and, again, that’s, I think, very good — and less protection against the infection.” This...